Crain’s Health Pulse – August 27, 2018
A new way to prevent nonfatal blood clots and pulmonary embolism in certain high-risk patients could have significant public health implications, according to a new study from Northwell Health’s Feinstein Institute for Medical Research and additional partners.
The study, published in The New England Journal of Medicine on Sunday, involves patients who had been hospitalized for acute illness. The researchers found that administering oral anticoagulants to such patients after they were discharged could reduce cases of nonfatal blood clots and pulmonary embolism.
There is a significant unmet need when it comes to preventing blood clots in this group, said Feinstein Institute research professor Dr. Alex Spyropoulos. Doing so has the potential to lower patient readmissions and associated costs.
In the U.S. alone, there are 8 million acutely ill, hospitalized patients. “Medically ill patients are at greater risk for developing blood clots while in the hospital and for up to three months afterward,” the Feinstein Institute said.
The Feinstein Institute and Spyropoulos worked on the study with partners including the University of Oklahoma and professor Gary Raskob as well as the Antithrombotic Trials Leadership and Steering Group and Janssen Pharmaceuticals.
“We were able to reduce instances of nonfatal blood clots and pulmonary embolism by more than half, which shows that the use of direct oral anticoagulants such as [Janssen’s] Xarelto after the hospitalization of medically ill patients could help prevent clots from forming,” Spyropoulos said. —J.H.